Literature DB >> 27125306

Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.

S Halbach1,2,3, M Köhler1,2,3, F M Uhl2,4, J Huber5,6, R Zeiser4,6,7,8, S Koschmieder9, K Aumann5, T Brummer1,6,7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27125306     DOI： 10.1038/leu.2016.92

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.

Authors:  Kohei Kometani; Misayo Aoki; Shin Kawamata; Yoriko Shinozuka; Takumi Era; Masafumi Taniwaki; Masakazu Hattori; Nagahiro Minato
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

2.  Mouse models as tools to understand and study BCR-ABL1 diseases.

Authors:  Steffen Koschmieder; Mirle Schemionek
Journal:  Am J Blood Res       Date:  2011-06-07

3.  The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia.

Authors:  Konrad Aumann; Silke Lassmann; Anja Schöpflin; Annette M May; Franziska U Wöhrle; Robert Zeiser; Cornelius F Waller; Dieter Hauschke; Martin Werner; Tilman Brummer
Journal:  Hum Pathol       Date:  2011-02-02       Impact factor: 3.466

4.  Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

Authors:  Steffen Koschmieder; Berthold Göttgens; Pu Zhang; Junko Iwasaki-Arai; Koichi Akashi; Jeffery L Kutok; Tajhal Dayaram; Kristin Geary; Anthony R Green; Daniel G Tenen; Claudia S Huettner
Journal:  Blood       Date:  2004-08-26       Impact factor: 22.113

5.  BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.

Authors:  A M Pendergast; L A Quilliam; L D Cripe; C H Bassing; Z Dai; N Li; A Batzer; K M Rabun; C J Der; J Schlessinger
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

6.  Function, regulation and pathological roles of the Gab/DOS docking proteins.

Authors:  Franziska U Wöhrle; Roger J Daly; Tilman Brummer
Journal:  Cell Commun Signal       Date:  2009-09-08       Impact factor: 5.712

7.  Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.

Authors:  Shengqing Gu; Wayne W Chan; Golam Mohi; Joel Rosenbaum; Azin Sayad; Zhibin Lu; Carl Virtanen; Shaoguang Li; Benjamin G Neel; Richard A Van Etten
Journal:  Blood       Date:  2016-01-15       Impact factor: 22.113

8.  Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.

Authors:  F U Wöhrle; S Halbach; K Aumann; S Schwemmers; S Braun; P Auberger; D Schramek; J M Penninger; S Laßmann; M Werner; C F Waller; H L Pahl; R Zeiser; R J Daly; T Brummer
Journal:  Leukemia       Date:  2012-08-03       Impact factor: 11.528

9.  Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.

Authors:  Sebastian Halbach; Zehan Hu; Christine Gretzmeier; Julia Ellermann; Franziska U Wöhrle; Jörn Dengjel; Tilman Brummer
Journal:  Cell Commun Signal       Date:  2016-02-24       Impact factor: 5.712

10.  Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells.

Authors:  Sebastian Halbach; Kristoffer Tg Rigbolt; Franziska U Wöhrle; Britta Diedrich; Christine Gretzmeier; Tilman Brummer; Jörn Dengjel
Journal:  Cell Commun Signal       Date:  2013-04-22       Impact factor: 5.712
View more
  5 in total

1.  BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.

Authors:  Ricarda Herr; Sebastian Halbach; Miriam Heizmann; Hauke Busch; Melanie Boerries; Tilman Brummer
Journal:  Oncogene       Date:  2018-01-12       Impact factor: 9.867

Review 2.  [Protein-dysregulation in human and murine myeloproliferative neoplasms].

Authors:  K Aumann
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

3.  Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways.

Authors:  Jianghong Cheng; Yanhong Zhong; Shuai Chen; Yan Sun; Lantang Huang; Yujia Kang; Baozhen Chen; Gang Chen; Fengli Wang; Yingpu Tian; Wenjie Liu; Gen-Sheng Feng; Zhongxian Lu
Journal:  FASEB J       Date:  2017-08-21       Impact factor: 5.191

4.  Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia.

Authors:  Katharina Sies; Corinna Spohr; Albert Gründer; Rumyana Todorova; Franziska Maria Uhl; Julia Huber; Robert Zeiser; Heike Luise Pahl; Heiko Becker; Konrad Aumann; Tilman Brummer; Sebastian Halbach
Journal:  Hemasphere       Date:  2019-02-22

5.  Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo.

Authors:  Corinna Spohr; Teresa Poggio; Geoffroy Andrieux; Katharina Schönberger; Nina Cabezas-Wallscheid; Melanie Boerries; Sebastian Halbach; Anna L Illert; Tilman Brummer
Journal:  Leukemia       Date:  2021-12-13       Impact factor: 11.528
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.